English
Home > Products > 5-AMINO-3-(TRIFLUOROMETHYL)PICOLINONITRILE

China 5-AMINO-3-(TRIFLUOROMETHYL)PICOLINONITRILE Factory

The key to our success is "Good Products Good quality, Reasonable Price and Efficient Service" for 5-AMINO-3-(TRIFLUOROMETHYL)PICOLINONITRILE,CAS NO 573762-62-6,573762-62-6,Apalutamide intermediate,Apalutamide advance intermediate, In order to expand our international market, we mainly supply our oversea customers Top quality performance products and service.
5-AMINO-3-(TRIFLUOROMETHYL)PICOLINONITRILE, We're in continuous service to our growing local and international clients. We aim to be worldwide leader in this industry and with this mind; it is our great pleasure to serve and bringing the highest satisfaction rates among the growing market.

Related Products

Hot Products

  • Lorcaserin hydrochloride

    Lorcaserin hydrochloride

    Product Name:Lorcaserin hydrochloride
    Molecular Formula:C11H15Cl2N
    Molecular Weight;232.15
    CAS Registry Number;846589-98-8
  • Creatine ethyl ester hydrochloride

    Creatine ethyl ester hydrochloride

    Product Name:Creatine ethyl ester hydrochloride
    Molecular Formula:C6H14ClN3O2
    Molecular Weight:195.65
    CAS Registry Number:15366-32-2
  • Benidipine hydrochloride

    Benidipine hydrochloride

    Product Name:Benidipine hydrochloride
    Molecular Formula:C28H31N3O6
    Molecular Weight;505.56
    CAS Registry Number;91599-74-5
  • Cilnidipine

    Cilnidipine

    Product Name:Cilnidipine
    Molecular Formula:C27H28N2O7
    Molecular Weight;492.52
    CAS Registry Number;132203-70-4
  • 4-chloro-7-Methoxyquinoline-6-carboxaMide

    4-chloro-7-Methoxyquinoline-6-carboxaMide

    Product Name:4-chloro-7-Methoxyquinoline-6-carboxaMide
    Molecular Formula:C11H9ClN2O2
    Molecular Weight:236.65
    CAS Registry Number:417721-36-9
  • (S)-(+)-Mandelic acid

    (S)-(+)-Mandelic acid

    Product Name:(S)-(+)-Mandelic acid
    Molecular Formula:C8H8O3
    Molecular Weight:152.15
    CAS Registry Number:17199-29-0
  • Related Blog
  • Reviews

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • CAS 148553-50-8 What is Pregabalin?

    Pregabalin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses within the brain that cause seizures. Pregabalin also affects chemicals within the brain that send pain signals across the systema nervosum.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept